Duragesic-100 and Joint effusion - a phase IV clinical study of FDA data

Summary:

Joint effusion is reported as a side effect among people who take Duragesic-100 (fentanyl), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Zometa, and have Metastases to bone.

The phase IV clinical study analyzes which people have Joint effusion when taking Duragesic-100. It is created by eHealthMe based on reports of 19,454 people who have side effects when taking Duragesic-100 from the FDA, and is updated regularly.

What is Duragesic-100?

Duragesic-100 has active ingredients of fentanyl. It is often used in pain. eHealthMe is studying from 19,509 Duragesic-100 users. Check the latest studies of Duragesic-100.

What is Joint effusion?

Joint effusion (presence of extra fluid in joint covering) is found to be associated with 869 drugs and 750 conditions by eHealthMe. Check the latest studies of Joint effusion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

19,454 people reported to have side effects when taking Duragesic-100.
Among them, 94 people (0.48%) have Joint effusion.

Could Duragesic-100 cause Joint effusion?

Among these 94 people:

How long have people been on Duragesic-100 when they have Joint effusion? *

What is the gender of people who have Joint effusion when taking Duragesic-100? *

female: 80.43 %
male: 19.57 %

What is the age of people who have Joint effusion when taking Duragesic-100? *

What are other drugs people take besides Duragesic-100? *

What are other side effects people have besides Joint effusion? *

Osteonecrosis Of Jaw (death of bone of jaw): 87 people, 92.55%
Joint Pain: 81 people, 86.17%
Chest Pain: 72 people, 76.60%
Dyspnea (difficult or laboured breathing): 65 people, 69.15%
Anaemia (lack of blood): 64 people, 68.09%
Stress And Anxiety: 60 people, 63.83%
Fall: 59 people, 62.77%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 59 people, 62.77%
Metastases To Bone (cancer spreads to bone): 57 people, 60.64%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 53 people, 56.38%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 39 people, 41.49%
Breast Cancer: 20 people, 21.28%
Multiple Myeloma (cancer of the plasma cells): 13 people, 13.83%
Transient Ischaemic Attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow)): 13 people, 13.83%
Sleep Disorder: 11 people, 11.70%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 11 people, 11.70%
Prostate Cancer: 9 people, 9.57%
Muscle Spasms (muscle contraction): 9 people, 9.57%
Breast Cancer Metastatic: 8 people, 8.51%
Constipation: 8 people, 8.51%

* Approximation only. Some reports may have incomplete information.

Do you take Duragesic-100 and have Joint effusion?

- Check whether Joint effusion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Duragesic-100:

Duragesic-100 (19,509 reports)

Joint effusion treatments and more:

Joint effusion (9,947 reports)

Browse all side effects of Duragesic-100:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Joint effusion:

Joint effusion (869 drugs)

Browse all the conditions that are associated with Joint effusion:

Joint effusion (750 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fentanyl (the active ingredients of Duragesic-100) and Duragesic-100 (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.